Skin accumulation of advanced glycation end-products predicts kidney outcomes in type 2 diabetes: results from the Brazilian Diabetes Study

Autor(es)

Barreto, Joaquim ; Martins, Marilia ; Borges, Cynthia M. ; Vitte, Sofia Helena ; Nadruz Jr, Wilson ; de Oliveira, Rodrigo Bueno ; Sposito, Andrei C.

• Tipo de documento: Artigo Científico
• Fonte: J. Bras. Nefrol.; v. 46, n. 4, p. 6-pg., 2024-01-01.

Resumo

The accumulation of advanced glycation end-products (AGEs) elicits morphofunctional kidney impairment. AGEs levels can be noninvasively estimated by skin autofluorescence (SAF). We explored whether high SAF predicts kidney outcomes in type 2 diabetes (T2D) individuals. The study was conducted as a predefined analysis of the Brazilian Diabetes Study, a prospective single-center cohort of T2D adults. Data from 155 individuals followed for up to 1716 days were considered. The incidence of major adverse kidney events (MAKE) was 9.6%. Individuals with above-median SAF had a higher incidence of MAKEs (4.6% vs. 21%; p = 0.002), with an HR of 3.39 [95% CI: 1.06-10.85; p = 0.040] after adjustment by age and gender. The mean adjusted eGFR change was 1.08 units (SE: 1.15; 95%CI: -1.20, 3.37) in the low SAF and -5.19 units [SE: 1.93; 95%CI: -9.10, -1.29] in the high SAF groups (between- subject difference: F: 5.62, p = 0.019). The high-SAF group had a greater prevalence of rapid decliners than the low-SAF group (36.7% vs. 15.8%; p = 0.028). In conclusion, high SAF was related to increased incidence of MAKEs and faster decline in eGFR among T2D subjects. This should be considered by healthcare providers when identifying individuals more prone to diabetes-related kidney complications. (AU)

• Processo FAPESP: 22/15002-8 - Efeitos da dapagliflozina no tecido ósseo de pacientes em hemodiálise
• Beneficiário: Rodrigo Bueno de Oliveira
• Modalidade de apoio: Auxílio à Pesquisa - Regular